Palvella Therapeutics gets third year of FDA orphan grant funding for QTORIN rapamycin Phase 3 SELVA trial

Funding supports the SELVA trial and open-label extension of QTORIN 3.9% rapamycin gel for microcystic lymphatic malformations. Palvella said it completed a rolling NDA submission in August 2026, targeting a potential U.S. launch in H1 2027 if approved.